Published in Fibrogenesis Tissue Repair on June 06, 2012
Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med (2014) 2.77
Bone marrow-derived stromal cells are invasive and hyperproliferative and alter transforming growth factor-α-induced pulmonary fibrosis. Am J Respir Cell Mol Biol (2014) 2.12
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med (2016) 0.78
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest (2004) 7.91
Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med (1998) 6.22
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med (2004) 6.02
Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest (2004) 5.97
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (1998) 4.88
Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 4.41
EMT: when epithelial cells decide to become mesenchymal-like cells. J Clin Invest (2009) 4.41
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med (2010) 4.19
CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol (2005) 4.02
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol (2007) 3.33
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am J Respir Cell Mol Biol (2006) 2.68
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med (2000) 2.63
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med (2009) 2.63
Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem Biophys Res Commun (2006) 2.52
Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol (2003) 2.51
Fibrocytes are a potential source of lung fibroblasts in idiopathic pulmonary fibrosis. Int J Biochem Cell Biol (2008) 2.42
Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med (2006) 2.34
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest (2010) 1.90
Fibrocyte CXCR4 regulation as a therapeutic target in pulmonary fibrosis. Int J Biochem Cell Biol (2009) 1.90
The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol (1987) 1.76
Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (2010) 1.66
Essential roles of the CC chemokine ligand 3-CC chemokine receptor 5 axis in bleomycin-induced pulmonary fibrosis through regulation of macrophage and fibrocyte infiltration. Am J Pathol (2007) 1.44
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis. Cytokine (2003) 1.42
The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax (1998) 1.29
Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair (2011) 1.26
Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med (2010) 1.21
Idiopathic pulmonary fibrosis and pirfenidone. Eur Respir J (2010) 1.18
Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.14
The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J (2002) 1.13
Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (2003) 1.11
Chemokine (C-C motif) ligand 2 mediates direct and indirect fibrotic responses in human and murine cultured fibrocytes. Fibrogenesis Tissue Repair (2011) 1.08
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev (2003) 0.93